These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36531260)

  • 21. A prospective evaluation of synergistic effect of sulbactam and tazobactam combination with meropenem or colistin against multidrug resistant Acinetobacter baumannii.
    Marie MA; Krishnappa LG; Alzahrani AJ; Mubaraki MA; Alyousef AA
    Bosn J Basic Med Sci; 2015 Oct; 15(4):24-9. PubMed ID: 26614848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced bacterial killing with a combination of sulbactam/minocycline against dual carbapenemase-producing Acinetobacter baumannii.
    Chandran S; Manokaran Y; Vijayakumar S; Shankar BA; Bakthavatchalam YD; Dwarakanathan HT; Yesudason BL; Veeraraghavan B
    Eur J Clin Microbiol Infect Dis; 2023 May; 42(5):645-651. PubMed ID: 36905566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro synergistic effect of colistin and ampicillin/sulbactam with several antibiotics against clinical strains of multi-drug resistant Acinetobacter baumannii.
    Shafiee F; Naji Esfahani SS; Hakamifard A; Soltani R
    Indian J Med Microbiol; 2021 Jul; 39(3):358-362. PubMed ID: 33906750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU.
    Sheng WH; Wang JT; Li SY; Lin YC; Cheng A; Chen YC; Chang SC
    Diagn Microbiol Infect Dis; 2011 Jul; 70(3):380-6. PubMed ID: 21558048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ultrastructural changes caused by the combination of intravenous immunoglobulin with meropenem, amikacin and colistin in multidrug-resistant Acinetobacter baumannii.
    Lima FCG; Oliveira-Júnior JB; Cavalcanti CLB; Veras DL; Freitas CF; Sandes JM; da Silva EM; da Rocha DAM; Alves LC; Brayner FA
    Microb Pathog; 2020 Dec; 149():104437. PubMed ID: 33045338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trend of extensively drug-resistant Acinetobacter baumannii and the remaining therapeutic options: a multicenter study in Tehran, Iran over a 3-year period.
    Jasemi S; Douraghi M; Adibhesami H; Zeraati H; Rahbar M; Boroumand MA; Aliramezani A; Ghourchian S; Mohammadzadeh M
    Lett Appl Microbiol; 2016 Dec; 63(6):466-472. PubMed ID: 27626896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro interactions of ambroxol hydrochloride or amlodipine in combination with antibacterial agents against carbapenem-resistant Acinetobacter baumannii.
    Wang Y; Li X; Wang D; Sun S; Lu C
    Lett Appl Microbiol; 2020 Mar; 70(3):189-195. PubMed ID: 31808159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acinetobacter baumannii in Southern Croatia: clonal lineages, biofilm formation, and resistance patterns.
    Kaliterna V; Kaliterna M; Hrenović J; Barišić Z; Tonkić M; Goic-Barisic I
    Infect Dis (Lond); 2015; 47(12):902-7. PubMed ID: 26365683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacodynamic Effects of Sulbactam/Meropenem/Polymyxin-B Combination Against Extremely Drug Resistant
    Menegucci TC; Fedrigo NH; Lodi FG; Albiero J; Nishiyama SAB; Mazucheli J; Carrara-Marroni FE; Voelkner NMF; Gong H; Sy SKB; Tognim MCB
    Microb Drug Resist; 2019 Nov; 25(9):1266-1274. PubMed ID: 31216222
    [No Abstract]   [Full Text] [Related]  

  • 30. In vitro synergistic antimicrobial activity of a combination of meropenem, colistin, tigecycline, rifampin, and ceftolozane/tazobactam against carbapenem-resistant Acinetobacter baumannii.
    Ju YG; Lee HJ; Yim HS; Lee MG; Sohn JW; Yoon YK
    Sci Rep; 2022 May; 12(1):7541. PubMed ID: 35534512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of the novel fluorocycline TP-6076 against carbapenem-resistant Acinetobacter baumannii.
    Seifert H; Stefanik D; Olesky M; Higgins PG
    Int J Antimicrob Agents; 2020 Jan; 55(1):105829. PubMed ID: 31669740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro and in vivo efficacy of cefiderocol plus tigecycline, colistin, or meropenem against carbapenem-resistant Acinetobacter baumannii.
    Ni W; Wang Y; Ma X; He Y; Zhao J; Guan J; Li Y; Gao Z
    Eur J Clin Microbiol Infect Dis; 2022 Dec; 41(12):1451-1457. PubMed ID: 36201141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome.
    Kuo LC; Lai CC; Liao CH; Hsu CK; Chang YL; Chang CY; Hsueh PR
    Clin Microbiol Infect; 2007 Feb; 13(2):196-198. PubMed ID: 17328733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Individual or Combined Effects of Meropenem, Imipenem, Sulbactam, Colistin, and Tigecycline on Biofilm-Embedded Acinetobacter baumannii and Biofilm Architecture.
    Wang YC; Kuo SC; Yang YS; Lee YT; Chiu CH; Chuang MF; Lin JC; Chang FY; Chen TL
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4670-6. PubMed ID: 27216052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic effects of sulbactam in multi-drug-resistant Acinetobacter baumannii.
    Temocin F; Erdinc FS; Tulek N; Demirelli M; Ertem G; Kinikli S; Koksal E
    Braz J Microbiol; 2015; 46(4):1119-24. PubMed ID: 26691470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activities of carbapenems in combination with amikacin, colistin, or fosfomycin against carbapenem-resistant Acinetobacter baumannii clinical isolates.
    Singkham-In U; Chatsuwan T
    Diagn Microbiol Infect Dis; 2018 Jun; 91(2):169-174. PubMed ID: 29433997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii.
    Gill CM; Santini D; Takemura M; Longshaw C; Yamano Y; Echols R; Nicolau DP
    J Antimicrob Chemother; 2023 Apr; 78(4):983-990. PubMed ID: 36775993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The synergic and addictive activity of biogenic silver nanoparticle associated with meropenem against carbapenem-resistant Acinetobacter baumannii.
    Allend SO; Oliveira Garcia M; da Cunha KF; de Albernaz DTF; Panagio LA; Nakazaro G; Reis GF; Oliveira TL; Neto ACPS; Hartwig DD
    J Appl Microbiol; 2024 Mar; 135(3):. PubMed ID: 38383758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Various antibiotic combinations against carbapenem resistant Acinetobacter baumannii infections and in vitro synergy test results (2002-2016)].
    Zarakolu P; Ayaz ÇM; Metan G
    Mikrobiyol Bul; 2018 Apr; 52(2):190-197. PubMed ID: 29933736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating the antibacterial effect of meropenem-loaded chitosan/sodium tripolyphosphate (TPP) nanoparticles on Acinetobacter baumannii isolated from hospitalized patients.
    Amini MS; Baseri Salehi M; Bahador N
    BMC Infect Dis; 2024 Jun; 24(1):631. PubMed ID: 38914964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.